| Literature DB >> 35820815 |
Jiansheng Wang1, Yuanpeng Lv2, Weiwei Yang2, Peng Zhao2, Changfu Yin3.
Abstract
BACKGROUND: The aim of this study was to elucidate the epidemiological features of carbapenemase-producing Enterobacterales (CPE) in the pediatric and neonatal patients, to describe clinical characteristics of neonatal patients with CPE infections, and to assess risk factors for neonatal rectal colonization with CPE.Entities:
Keywords: Carbapenemase-producing; Escherichia coli; Infection prevention; Klebsiella pneumoniae; Risk factors
Mesh:
Substances:
Year: 2022 PMID: 35820815 PMCID: PMC9277881 DOI: 10.1186/s12866-022-02585-z
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 4.465
Distribution of carbapenemase-producing Enterobacterales isolates in infant patients
| 0–3 days age group | 4–28 days age group | 29–365 days age group | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sequence types of CPKP | No | Sequence types of CPEC | No | Sequence types of | No | Sequence types of CPEC | No | Sequence types of CPKP | No | Sequence types of CPEC | No | |||
| First stool screening | ST13 ST20 ST36 ST2068 | 2 49 18 41 | ST1 | 1 | ST13 ST20 ST36 ST2068 ST45 | 3 16 14 20 1 | ST767 ST167 ST524 | 1 1 1 | ST20 ST36 ST2068 ST2267 | 8 2 5 1 | ST196 ST167 ST4542 | 1 2 1 | ||
| Second stool screening | ST17 ST23 ST20 | 32 4 3 | ST325 | 20 | ST17 ST4 ST2068 | 12 4 1 | ST325 | 6 | ST17 ST23 ST45 ST685 ST36 | 1 1 1 1 2 | ST398 ST469 ST83 | 1 1 1 | ||
| Clinical specimens | ST11 ST13 ST20 ST36 ST39 ST307 ST2068 ST17 ST23 ST1786 | 29 1 33 13 13 15 4 2 2 1 | ST471 ST469 ST325 | 1 1 1 | ST11 ST20 ST36 ST2068 ST17 ST1655 ST307 | 8 9 2 2 3 1 3 | ST325 | 1 | ST11 ST20 ST39 ST36 ST719 ST23 ST307 | 3 4 1 3 1 1 1 | ST325 | 1 | ||
ST sequence type, CPKP carbapenemase-producing Klebsiella pneumoniae, CPEC carbapenemase-producing Escherichia coli
Demographic and clinical characteristics of seventy-six patients with CPE pneumonia according to carbapenemase types
| Variables | Total ( | IMP-4 ( | KPC-2 ( | NDM-1 ( |
|---|---|---|---|---|
| Gender (male) | 55 (72.37) | 9 (69.23) | 16 (72.73) | 30 (73.17) |
| Prematurity | 61 (80.26) | 11 (84.62) | 18 (81.82) | 32 (78.05) |
| Cesarean section | 51 (67.11) | 8 (61.54) | 17 (77.27) | 26 (63.41) |
| Gestational age (d) | 237.09 ± 23.34 | 233.08 ± 17.62 | 231.55 ± 23.35 | 241.34 ± 26.27 |
| Birth weight (g) | 2103.62 ± 876.30 | 2003.08 ± 752.85 | 1857.95 ± 728.66 | 2267.32 ± 962.85 |
| Hospital stay (d) | 24.82 ± 13.22 | 24.54 ± 10.18 | 27.32 ± 14.27 | 23.59 ± 13.59 |
| Hospital stay before CPE isolation (d) | 7.64 ± 5.72 | 9.69 ± 6.05 | 7.91 ± 4.97 | 6.85 ± 5.95 |
| Hypocalcemia | 40 (52.63) | 2 (15.38) | 12 (54.55) | 26 (63.41) |
| Respiratory distress syndrome | 29 (38.16) | 4 (30.77) | 7 (31.82) | 18 (43.90) |
| Acidosis | 27 (35.53) | 3 (23.08) | 9 (40.91) | 15 (36.59) |
| Anemia | 43 (56.58) | 7 (53.85) | 14 (63.64) | 22 (53.66) |
| Hypoxic-ischemic encephalopathy | 37 (48.68) | 9 (69.23) | 10 (45.45) | 18 (43.90) |
| Acleistocardia | 29 (38.16) | 5 (38.46) | 1 (4.55) | 23 (56.10) |
| Pulmonary hypertension | 11 (14.47) | 1 (7.69) | 0 (0) | 10 (24.39) |
| Respiratory failure | 32 (42.11) | 6 (46.15) | 6 (27.27) | 20 (48.78) |
| Pulmonary membrane disease | 35 (46.05) | 7 (53.85) | 14 (63.64) | 14 (34.15) |
| Nasogastric feeding | 55 (72.37) | 8 (61.54) | 17 (77.27) | 30 (73.17) |
| Gastric lavage | 74 (97.37) | 11 (84.62) | 22 (100) | 41 (100) |
| Enema | 24 (31.58) | 0 (0) | 7 (31.82) | 17 (41.46) |
| Mechanical ventilation | 55 (72.37) | 9 (69.23) | 14 (63.64) | 32 (78.05) |
| Peripherally inserted central catheter | 24 (31.58) | 4 (30.77) | 8 (36.36) | 12 (29.27) |
| Infection with | 74 (97.37) | 13 (100) | 22 (100) | 39 (95.12) |
| Infection with | 2 ( 2.63) | 0 (0) | 0 (0) | 2 (4.88) |
| Previous antibiotic exposure | ||||
| β-lactam/β-lactamase inhibitor combinations | 59 (77.63) | 13 (100) | 22 (100) | 24 (58.54) |
| Gentamicin | 5 (6.58) | 3 (23.08) | 0 (0) | 2 (4.88) |
| Cephalosporins | 24 (31.58) | 0 (0) | 1 (4.55) | 23 (56.10) |
| Carbapenems | 18 (23.68) | 5 (38.46) | 5 (22.73) | 8 (19.51) |
| Change in antibiotic treatment after CRE isolation | 62 (81.58) | 12 (92.31) | 16 (72.73) | 34 (82.93) |
| Ciprofloxacin | 13 (17.11) | 7 (58.33) | 0 (0) | 6 (17.65) |
| Meropenem | 47 (61.84) | 4 (33.33) | 16 (100) | 27 (79.41) |
| β-lactam/β-lactamase inhibitor combinations | 2 (2.63) | 1 (8.33) | 0 (0) | 1 (2.94) |
| Outcome | ||||
| Cure | 63 (82.89) | 12 (92.31) | 17 (77.27) | 34 (82.93) |
| Improvement | 13 (17.11) | 1 (7.69) | 5 (22.73) | 7 (17.07) |
CPE carbapenemase-producing Enterobacterales
Risk factors assoclated with rectal colonization of NDM-1-producing Enterobacterales in neonatal patient
| Variables | 4-28 days age group | 0-3 days age group | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Carbapenem-susceptible | Carbapenem-resistant | Univariate analysis | Multivariate analysis | Carbapenem-susceptible | Carbapenem-resistant | Univariate analysis | Multivariate analysis | |||
| Age of admission (d) | 9.47 ± 7.48 | 10.18 ± 7.27 | 0.222 | |||||||
| Gender (male) | 90 (62.5) | 40 (56.34) | 0.385 | 78 (52) | 80 (52.98) | 0.913 | ||||
| Gestational age (d) | 271.67 ± 25.26 | 270.30 ± 14.39 | 0.069 | 267.77 ± 18.65 | 250.57 ± 23.81 | < 0.001 | ||||
| Birth weight (g) | 3306.33 ± 568.21 | 3239.65 ± 526.20 | 0.592 | 3080.97 ± 665.74 | 2637.55 ± 880.633 | < 0.001 | ||||
| Prematurity | 10 (6.94) | 8 (11.27) | 0.282 | 42 (28) | 93 (61.59) | < 0.001 | ||||
| Cesarean section | 54 (37.5) | 43 (60.56) | 0.001 | 2.55 (1.37–4.74) | 0.003 | 66 (44) | 100 (66.23) | < 0.001 | 2.92 (1.69–5.05) | < 0.001 |
| Pulmonary infection | 34 (23.61) | 20 (28.17) | 0.469 | 18 (12) | 23 (15.23) | 0.414 | ||||
| Respiratory distress syndrome | 12 (8.33) | 5 (7.04) | 0.741 | 96 (64) | 122 (80.79) | 0.001 | ||||
| Acidosis | 1 (0.69) | 1 (1.41) | 0.552 | 22 (14.67) | 53 (35.10) | < 0.001 | 2.25 (1.17–4.33) | 0.016 | ||
| Hyperbilirubinemia | 108 (75) | 47 (66.20) | 0.176 | 45 (30) | 13 (8.61) | < 0.001 | ||||
| Respiration failure | 1 (0.69) | 2 (2.82) | 0.254 | 7 (4.67) | 38 (25.17) | < 0.001 | 3.46 (1.41–8.45) | 0.007 | ||
| Acleistocardia | 67 (46.53) | 44 (61.97) | 0.033 | 96 (64) | 83 (54.97) | 0.139 | ||||
| Hypocalcemia | 6 (4.17) | 3 (4.23) | > 0.999 | 31 (20.67) | 59 (39.07) | < 0.001 | ||||
| Anemia | 15 (10.42) | 10 (14.08) | 0.430 | 11 (7.33) | 18 (11.92) | 0.177 | ||||
| β-lactam/β-lactamase inhibitor | 34 (23.61) | 20 (28.17) | 0.469 | 46 (30.67) | 52 (34.44) | 0.485 | ||||
| Cephalosporins | 52 (36.11) | 40 (56.34) | 0.005 | 2.12 (1.14–3.94) | 0.017 | 79 (52.67) | 94 (62.25) | 0.093 | ||
| Meropenem | 10 (6.94) | 6 (8.45) | 0.692 | 2 (1.33) | 10 (6.62) | 0.019 | ||||
| Oxygen inhalation | 26 (18·06) | 15 (21.13) | 0.590 | 60 (40) | 100 (66.23) | < 0.001 | ||||
| Sputum suction | 62 (43.06) | 36 (50.70) | 0.290 | 108 (72) | 143 (94.7) | < 0.001 | ||||
| Gastric lavage | 11 (7.64) | 16 (22.54) | 0.002 | 3.44 (1.44–8.22) | 0.005 | 97 (64.67) | 138 (91.39) | < 0.001 | 3.09 (1.49–6.39) | 0.002 |
| Nasogastric feeding | 12 (8.33) | 13 (18.31) | 0.032 | 56 (37.33) | 85 (59.29) | 0.001 | ||||
| Enema | 16 (11.11) | 13 (18.31) | 0.146 | 40 (26.67) | 91 (60.26) | < 0.001 | 2.84 (1.65–4.91) | < 0.001 | ||
| Endotracheal intubation | 7 (4.67) | 32 (21.19) | < 0.001 | |||||||
| Residence in rural area | 46 (31.94) | 37 (52.11) | 0.004 | 2.22 (1.19–4.13) | 0.012 | 72 (48) | 72 (47·68) | 0.956 | ||
Abbreviations: OR odds ratio, CI confidence interval
Fig. 1Distribution of neonatal patients with NDM-1 producing Klebdieella pneumoniae or Escherichia coli of common STs according to the quarters. Abbreviations: ST, sequence type; CPKP, carbapenemase-producing Klebdieella pneumoniae; CPEC, carbapenemase-producing Escherichia coli
Fig. 2Distribution of infant patients with NDM-1 producing Klebdieella pneumoniae strains of three representative STs according to months. Abbreviations: KP, Klebdieella pneumoniae; ST, sequence type